h56
Vaccineexperimental
Clinical trial activity
4 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 21, 2014 (NCT02375698)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- h56
- h56
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03512249 | Phase 2 | Sep 30, 2018 | Aeras, Statens Serum Institut |
| NCT03265977 | Phase 2 | Jun 30, 2018 | Aeras, Aurum Institute, National Institute for Medical Research, Tanzania, South African Tuberculosis Vaccine Initiative (SATVI), Statens Serum Institut, University of Bergen, University of Copenhagen, University of Oslo |
| NCT02503839 | Phase 1 | Nov 1, 2015 | Osaka University, Statens Serum Institut, University of Bergen, University of Oslo |
| NCT02375698 | Phase 1 | Nov 21, 2014 | Aeras, Statens Serum Institut |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Statens Serum Institut | Academic/Hospital | 4 | 0 | 2 | 2014 |
| Aeras | Academic/Hospital | 3 | 3 | 2 | 2014 |
| University of Bergen | Academic/Hospital | 2 | 0 | 2 | 2015 |
| University of Oslo | Academic/Hospital | 2 | 1 | 2 | 2015 |
| Aurum Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Institute for Medical Research, Tanzania | Government | 1 | 0 | 1 | 2018 |
| Osaka University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| South African Tuberculosis Vaccine Initiative (SATVI) | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2018 |
9 organizations
Page 1 / 1